IXICO PLC (LON:IXI) said the impact of the coronavirus pandemic has been modest on its business, with double-digit revenue growth expected this year and next.
The neuroscience data analytics specialist said it is confident of generating at least £9.1mln of revenue for the year to 30 September 2020, with £0.9mln in underlying profit (EBITDA) and positive operating cash.
READ: IXICO earnings rise in first half as order book continues to strengthen
This would represent revenue growth of 20% for the fourth year running, with EBITDA margins expected to increase to 10% from 6%, which would allow the AIM-quoted company to achieve its second year of profitability as a listed company.
Directors also said they expect the company will continue to maintain double-digit revenue growth across the following year to September 2021 as well as continuing to invest in the company to ensure it is ready to scale up as clinical trials delayed by the COVID-19 crisis are initiated.
“I am delighted that the impact of COVID-19 on our expected revenue growth has been minimised by fully leveraging the capabilities of our technology platform,” said chief executive Giulio Cerroni.
“Our remote access business model, which utilises our proprietary TrialTracker platform, coupled with our centralised artificial intelligence data analytics capabilities has mitigated any potential material disruption to our business operations.”
He said there had been some impact from some new trials being postponed, IXICO was using this time to prepare for what is expected to be a rapid initiation of additional client studies towards the end of 2020 and across 2021.